GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomea Fusion Inc (NAS:BMEA) » Definitions » Shares Outstanding (EOP)

Biomea Fusion (Biomea Fusion) Shares Outstanding (EOP) : 35.87 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Biomea Fusion Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Biomea Fusion's shares outstanding for the quarter that ended in Dec. 2023 was 35.87 Mil.

Biomea Fusion's quarterly shares outstanding increased from Sep. 2023 (35.70 Mil) to Dec. 2023 (35.87 Mil). It means Biomea Fusion issued new shares from Sep. 2023 to Dec. 2023 .

Biomea Fusion's annual shares outstanding increased from Dec. 2022 (29.56 Mil) to Dec. 2023 (35.87 Mil). It means Biomea Fusion issued new shares from Dec. 2022 to Dec. 2023 .


Biomea Fusion Shares Outstanding (EOP) Historical Data

The historical data trend for Biomea Fusion's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomea Fusion Shares Outstanding (EOP) Chart

Biomea Fusion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
10.71 27.27 29.12 29.56 35.87

Biomea Fusion Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.56 29.65 35.63 35.70 35.87

Competitive Comparison of Biomea Fusion's Shares Outstanding (EOP)

For the Biotechnology subindustry, Biomea Fusion's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomea Fusion's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's Shares Outstanding (EOP) falls into.



Biomea Fusion Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Biomea Fusion  (NAS:BMEA) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Biomea Fusion Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Biomea Fusion's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomea Fusion (Biomea Fusion) Business Description

Traded in Other Exchanges
N/A
Address
900 Middlefield Road, 4th Floor, Redwood City, CA, USA, 94063
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Executives
Juan Pablo Frias officer: Chief Medical Officer 900 MIDDLEFIELD ROAD, 4TH FLOOR, C/O BIOMEA FUSION, INC., REDWOOD CITY CA 94063
A2a Pharmaceuticals, Inc. 10 percent owner 59 5TH AVE, NEW YORK NY 10003
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen director, 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Hitchcock Michael J.m. director C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Franco Valle officer: Chief Financial Officer 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Elizabeth Faust director C/O BIOMEA FUSION, INC., 900 MIDDLEFIELD RD., 4TH FL, REDWOOD CITY CA 94063
Sumita Ray director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Sotirios Stergiopoulos director C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Rainer M Erdtmann director, 10 percent owner, officer: President and COO 1073 ARLINGTON BLVD., EL CERRITO CA 94530
Thomas Andrew Butler director, 10 percent owner, officer: CEO 726 MAIN STREET, REDWOOD CITY CA 94065
Eric Aguiar director 888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Biomea Health, Llc 10 percent owner 726 MAIN STREET, REDWOOD CITY CA 94063

Biomea Fusion (Biomea Fusion) Headlines

From GuruFocus